ArcherDX, Inc. today announced that Jason Myers, Ph.D., Chief Executive Officer and co-founder of ArcherDX, will participate in a fireside chat at Cowen’s 2020 Liquid Biopsy Summit on Thursday, September 24th at 2:00 p.m. Eastern Daylight Time (EDT) / 12:00 p.m. Mountain Daylight Time (MDT).
Join leading researchers from around the world at the 5th Annual Liquid Biopsy Summit to discuss process and technology refinements that will enable molecular liquid biopsies to become a fulcrum in the future of precision medicine
Interested parties may access a live and archived webcast of the presentation on the “News & Events” section of the company website.
Event: Cowen’s 2020 Liquid Biopsy Summit
Presenter: Jason Myers, Ph.D., Chief Executive Officer and co-founder, ArcherDX
Date: Thursday, September 24
Time: 2:00 – 2:25 p.m. EDT
ArcherDX is a leading genomic analysis company democratizing precision oncology through a suite of products and services that are highly accurate, personal, actionable and easy to use in local settings. Our Archer® platform, with our proprietary Anchored Multiplex PCR (AMP™) chemistry at the core, has enabled us to develop industry-leading products and services to optimize therapy and enable cancer monitoring across sample types. We develop and commercialize research use only (RUO) products, are developing in vitro diagnostic (IVD) products, and offer services that meet the unique needs of our customers and their clinical applications. Our research product portfolio consists of VariantPlex®, FusionPlex®, LiquidPlex™ and Immunoverse™. IVD products currently in development for solid tumor biomarker identification and Personalized Cancer Monitoring (PCM™) have both received Breakthrough Device Designation from the FDA. ArcherDX is headquartered in Boulder, Colorado. Learn more at www.archerdx.com and follow @ArcherDXInc on Twitter, Facebook and LinkedIn.